OLYMPUS CORPORATION
7733・Prime Market・Precision Instruments
Business
Olympus traces its origins to an optical equipment manufacturer founded in 1919, and is now a medtech company specializing in two segments: the Gastrointestinal Endoscopy Solutions Business and the Surgical Intervention Business. In the gastrointestinal endoscopy field, it offers gastrointestinal endoscopy systems, treatment devices, and medical services, while in the Surgical Intervention field, it operates in urology, respiratory, surgical endoscopy, energy devices, and other areas. The group includes 80 subsidiaries, 2 affiliated companies, and 1 jointly controlled entity, with North America, Europe, Asia, and Oceania as its primary markets, and hospitals, clinics, and other medical institutions as its main customers. Consolidated net sales for FY2026 (ending March 2026) reached ¥1,010,676 million, as the company pursues sustainable growth as a healthcare-focused enterprise.
Business Model
In the core Gastrointestinal Endoscopy Solutions Business, in addition to initial sales of advanced endoscopy systems (such as the EVIS X1), recurring revenue from consumable devices and Medical Services (maintenance, repair, etc.) supports the profit base. In the Surgical Intervention Business, the company provides equipment and devices for urology and respiratory applications. R&D expenses account for 10.9% of net sales (¥109,900 million), maintaining product competitiveness. A global direct sales structure and network of local subsidiaries ensure a high degree of customer contact.
Company Strengths
The company has rolled out scopes equipped with EDOF (Extended Depth of Field) technology as part of the EVIS X1 series, along with the EU-ME3 Endoscopic Ultrasound Observation System, across multiple markets, achieving double-digit growth in North America, Europe, and Asia/Oceania in the fourth quarter of FY2026 (ending March 2026). The Gastrointestinal Endoscopy Solutions Business posted revenue of ¥697,359 million, accounting for approximately 69% of total company revenue, establishing its position as the core business.
In Europe, the company has continued to post steady performance in the UK and other countries, centered on Olympus Europa SE & Co. KG, while also securing stable demand in Asia and Oceania. In the Medical Services field, recurring revenue driven by Europe has been expanding, with the high level of customer engagement enabled by its direct sales structure serving as a differentiating factor versus competitors.
R&D expenses for FY2026 (ending March 2026) amounted to ¥109.9 billion (10.9% of revenue), up 5.8% year on year. The company allocated ¥68.5 billion to the Gastrointestinal Endoscopy Solutions Business and ¥41.4 billion to the Surgical Intervention Business, advancing the OLYSENSE CAD/AI platform and next-generation scope development. Joint development of a next-generation endoscopy system with Sony is also ongoing.
ENVALITH's Perspective
Performance Trend
Revenue grew for five consecutive fiscal years, from ¥868,867 million in FY2022 (ending March 2022) to ¥1,010,676 million in FY2026 (ending March 2026), but the growth rate in FY2026 slowed to 1.3%. Excluding the impact of foreign exchange, revenue was effectively flat year on year. Operating profit in FY2026 (ending March 2026) fell 40.2% to ¥97,120 million from ¥162,462 million in the prior year. This was mainly due to a sharp increase in one-time expenses, including ¥26,872 million in organizational restructuring and workforce optimization costs, ¥10,781 million in quality-related expenses, and ¥12,085 million in impairment losses. Adjusted operating profit also declined, falling 24.0% year on year to ¥143,310 million, indicating a decline in underlying earnings power as well. Profit attributable to owners of the parent came to ¥68,172 million, down 42.2% year on year. As external factors, deterioration in the cost of sales ratio due to US tariffs (cost of sales ratio of 35.3%, a 3.8-point deterioration year on year) and intensifying competition in the Chinese market weighed on both revenue and profit.
Growth Strategy
Sustained growth led by the Gastrointestinal Endoscopy Solutions Business, combined with profit recovery driven by the reduction of one-time expenses and structural efficiency improvements
Leveraging continued solid demand in Europe, Asia, and Oceania, along with the effects of new products such as EDOF technology-equipped scopes and the EU-ME3, the company positions this business as the primary driver of revenue growth in FY2027 (ending March 2027) as well. In North America, double-digit growth was achieved in the fourth quarter, and continued sales promotion activities are expected.
Through the gradual reduction of expenses related to the Elevate quality assurance project (¥10,781 million in FY2026 (ending March 2026), a decrease of approximately ¥8,569 million year on year) and disciplined cost management under the new operating model, the company aims for operating profit of ¥136,500 million to ¥155,500 million (up 40.5% to 60.1% year on year) in FY2027 (ending March 2027).
The company continues corrective actions in response to the warning letter received from the FDA, allocating substantial resources across manufacturing, quality, supply chain, and R&D. Building on the results of FDA inspections conducted at eight sites in the second half of 2025, the company is advancing the maturity, consistency, and global standardization of its quality systems. Lifting the import alert is a prerequisite for normalizing product supply.
Through the development of endoluminal robotic products via Swan EndoSurgical, Inc. (45% equity interest) and collaboration with early-stage companies through an additional US$150 million investment in Olympus Innovation Ventures Fund II, the company aims to build a next-generation endoscopic healthcare ecosystem. There is potential for up to an additional US$206 million in investment over the next six years.
In response to intensifying competition and domestic preference policies in China, the company is advancing preparations for local production. It aims to diversify its regional portfolio by establishing a growth strategy for emerging markets and promoting tack-in M&A. Net sales in China for FY2026 (ending March 2026) decreased to ¥82,452 million from ¥95,738 million in the previous fiscal year, underscoring the urgency of the response.
Last updated: July 19, 2026